PurvalanolB , 10mMinDMSO , 212844-54-7
Synonym(s):
(2R)-2-[[6-[(3-Chloro-4-carboxyphenyl)amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-3-methyl-1-butanol;NG 95
CAS NO.：212844-54-7
Empirical Formula: C20H25ClN6O3
Molecular Weight: 432.9
MDL number: MFCD04118312
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB559.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 58.5 °C |
| Boiling point: | 660.6±65.0 °C(Predicted) |
| Density | 1.43±0.1 g/cm3(Predicted) |
| storage temp. | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
| solubility | DMSO: 37 mg/mL, soluble |
| form | solid |
| pka | 2.81±0.25(Predicted) |
| color | White to light yellow |
| InChIKey | ZKDXRFMOHZVXSG-HNNXBMFYSA-N |
Description and Uses
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Purvalanol B is a CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively). It is inactive against Cdk4/cyclin D1 as well as several other protein kinases. Purvalanol B is a 2,6,9-trisubstituted purine that, at micromolar doses, inhibits the growth of parasites, including Plasmodium.
Purvalanol B is a potent cyclin-dependent kinase 2 (CDK2) inhibitor. These cyclin-dependent kinases play key roles in the regulation of the cell cycle and small molecules that inhibit these proteins have therapeutic potential against various proliferative and neurodegenerative disorders.
Safety
| WGK Germany | 3 |
